{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:10:48Z","timestamp":1771513848944,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>History of malignant disease is a common exclusion criterion in clinical cancer trials, yet data on the impact of cancer survivorship on outcome in gastroesophageal cancer patients are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective association analyses of self-reported prior or concurrent malignancies with patient characteristics, tumor characteristics, symptoms and overall survival (OS) were performed in 1491 gastroesophageal cancers patients treated between 01\/01\/2000 and 31\/12\/2021 at the Medical University of Vienna.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1491 patients 255 (18%) had other primary cancer diagnoses, of which 185 (73%) occurred before, 52 (20%) at the same time as and 18 (7%) both before and at the same time as gastroesophageal cancer diagnosis. 205 (80%) patients had one, 43 (17%) had 2 and 7 (3%) had 3 other malignancies. History of other malignancies was associated with older age (p\u2009&lt;\u20090.0001), squamous cell histology (p\u2009=\u20090.018), less aggressive localized tumor stages (p\u2009=\u20090.037) and fewer acid reflux (p\u2009=\u20090.011). There was neither an association between history of other primary malignancies nor the number of other cancer entities and OS (p\u2009=\u20090.47; p\u2009=\u20090.43).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Self-reported history of other malignant diseases is frequent in a real-life European gastroesophageal cancer cohort and was not statistically significantly associated with outcome, but rather with older age and squamous cell histology. Our data emphasize that cancer survivors should not be categorically excluded from clinical cancer trials due to fear of dismal prognosis. Prospective research is warranted to improve eligibility for this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04036-3","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T03:34:50Z","timestamp":1756438490000},"page":"942-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-8732","authenticated-orcid":false,"given":"Hannah C.","family":"Puhr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luzia","family":"Berchtold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Zingerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Korpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Jomrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Asari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian F.","family":"Schoppmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7854-7781","authenticated-orcid":false,"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-1408","authenticated-orcid":false,"given":"Elisabeth S.","family":"Bergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-6797","authenticated-orcid":false,"given":"Anna S.","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0873","authenticated-orcid":false,"given":"Ayseg\u00fcl","family":"Ilhan-Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"4036_CR1","first-page":"100845","volume":"41","author":"TI Mamun","year":"2024","unstructured":"Mamun TI, Younus S, Rahman MH. Gastric cancer\u2014epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: an updated review. Cancer Treat Res Commun. 2024;41:100845.","journal-title":"Cancer Treat Res Commun"},{"key":"4036_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-59745-416-2_5","volume":"471","author":"I Soerjomataram","year":"2009","unstructured":"Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol. 2009;471:85\u2013105.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"4036_CR3","first-page":"e4552","volume":"11","author":"WP Skelton","year":"2019","unstructured":"Skelton WP, Ali A, Skelton MN, Federico R, Bosse R, Nguyen TC, et al. Analysis of overall survival in patients with multiple primary malignancies: a single-center experience. Cureus. 2019;11(4):e4552.","journal-title":"Cureus"},{"issue":"11","key":"4036_CR4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1634\/theoncologist.2011-0214","volume":"16","author":"AM Vander Walde","year":"2011","unstructured":"Vander Walde AM, Hurria A. Second malignancies among elderly survivors of cancer. Oncologist. 2011;16(11):1572\u201381.","journal-title":"Oncologist"},{"issue":"13","key":"4036_CR5","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","volume":"23","author":"CA Townsley","year":"2005","unstructured":"Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112\u201324.","journal-title":"J Clin Oncol"},{"issue":"33","key":"4036_CR6","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","volume":"35","author":"SM Lichtman","year":"2017","unstructured":"Lichtman SM, Harvey RD, Smit MAD, Rahman A, Thompson MA, Roach N, et al. Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol. 2017;35(33):3753\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4036_CR7","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4036_CR8","unstructured":"U.S. Food and Drug Administration. Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies. 2020 2024\/01\/05]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent."},{"issue":"33","key":"4036_CR9","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement. J Clin Oncol. 2017;35(33):3737\u201344.","journal-title":"J Clin Oncol"},{"issue":"10424","key":"4036_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0140-6736(23)02199-2","volume":"403","author":"A Leary","year":"2024","unstructured":"Leary A, Besse B, Andr\u00e9 F. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. Lancet. 2024;403(10424):406\u20138.","journal-title":"Lancet"},{"issue":"8","key":"4036_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/onco.13759","volume":"26","author":"GW Peters","year":"2021","unstructured":"Peters GW, Tao W, Wei W, Miccio JA, Jethwa KR, Cecchini M, et al. Publication bias in gastrointestinal oncology trials performed over the past decade. Oncologist. 2021;26(8):660\u20137.","journal-title":"Oncologist"},{"issue":"1","key":"4036_CR12","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.14694\/EdBook_AM.2014.34.e57","volume":"34","author":"LM Morton","year":"2014","unstructured":"Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014;34(1):e57-67.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"19","key":"4036_CR13","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1002\/cncr.30164","volume":"122","author":"N Donin","year":"2016","unstructured":"Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. 2016;122(19):3075\u201386.","journal-title":"Cancer"},{"issue":"13","key":"4036_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/CLEP.S304332","volume":"2021","author":"G Zheng","year":"2021","unstructured":"Zheng G, Sundquist K, Sundquist J, Chen T, F\u00f6rsti A, Hemminki A, et al. Second primary cancers after gastric cancer, and gastric cancer as second primary cancer. Clin Epidemiol. 2021;2021(13):515\u201325.","journal-title":"Clin Epidemiol"},{"issue":"10","key":"4036_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro S, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"10","key":"4036_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004.","journal-title":"Ann Oncol"},{"key":"4036_CR17","unstructured":"National Cancer Insititut - Division of Cancer Epidemiology & Genetics. Second Primary Cancers. 2024\/01\/05]; Available from: https:\/\/dceg.cancer.gov\/research\/what-we-study\/second-cancers."},{"issue":"7","key":"4036_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","volume":"122","author":"E Laconi","year":"2020","unstructured":"Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer. 2020;122(7):943\u201352.","journal-title":"Br J Cancer"},{"issue":"8","key":"4036_CR19","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","volume":"21","author":"VR Blair","year":"2020","unstructured":"Blair VR, McLeod M, Carneiro F, Coit DG, D\u2019Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386\u201397.","journal-title":"Lancet Oncol"},{"key":"4036_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.breast.2017.02.012","volume":"33","author":"AL Mahar","year":"2017","unstructured":"Mahar AL, Kagedan DJ, Hallet J, Coburn NG. Secondary gastric cancer malignancies following a breast cancer diagnosis: a population-based analysis. Breast. 2017;33:34\u20137.","journal-title":"Breast"},{"issue":"1","key":"4036_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10689-021-00235-3","volume":"21","author":"CR Boland","year":"2022","unstructured":"Boland CR, Yurgelun MB, Mraz KA, Boland PM. Managing gastric cancer risk in lynch syndrome: controversies and recommendations. Fam Cancer. 2022;21(1):75\u20138.","journal-title":"Fam Cancer"},{"issue":"15","key":"4036_CR22","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1001\/jama.287.15.1972","volume":"287","author":"N Shaheen","year":"2002","unstructured":"Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972\u201381.","journal-title":"JAMA"},{"key":"4036_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/11795476221150597","volume":"16","author":"DT Nguyen","year":"2023","unstructured":"Nguyen DT, Nguyen LM, Phan TL, Bui QV. One patient with 4 different primary cancers: a case report. Clin Med Insights Case Rep. 2023;16: 11795476221150597.","journal-title":"Clin Med Insights Case Rep"},{"issue":"1","key":"4036_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12891-020-03426-8","volume":"21","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Sun K, Yan T, Wei R, Guo W. Multiple primary tumors: a case report and review of the literature. BMC Musculoskelet Disord. 2020;21(1):394.","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"4036_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000440799","volume":"8","author":"CW Williamson","year":"2015","unstructured":"Williamson CW, Paravati A, Ghassemi M, Lethert K, Hua P, Hartman P, et al. Five simultaneous primary tumors in a single patient: a case report and review of the literature. Case Rep Oncol. 2015;8(3):432\u20138.","journal-title":"Case Rep Oncol"},{"issue":"4","key":"4036_CR26","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/cam4.3722","volume":"10","author":"X Bian","year":"2021","unstructured":"Bian X, Wang K, Wang Q, Yang L, Xia J, Wu W, et al. The impact of a prior malignancy on outcomes in gastric cancer patients. Cancer Med. 2021;10(4):1457\u201370.","journal-title":"Cancer Med"},{"issue":"5","key":"4036_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.12998\/wjcc.v10.i5.1485","volume":"10","author":"X Yin","year":"2022","unstructured":"Yin X, He XK, Wu LY, Yan SX. Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation. World J Clin Cases. 2022;10(5):1485\u201397.","journal-title":"World J Clin Cases"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04036-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:19:14Z","timestamp":1771510754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04036-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4036"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04036-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HC.P. has received travel support from Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre and Roche and received lecture honoraria from Eli Lilly. A.I-M.: Participation in advisory boards organized by MSD, Servier, Daiichi Sankyo and BMS, Lecture honoraria from Eli Lilly, Servier, BMS, MSD, Astellas and Daiichi Sankyo, Local PI for clinical trials sponsored by BMS and Roche, Consulting for Astellas and MSD, Travel support from BMS, Roche, Eli Lilly and Daiichi Sankyo. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier. AS.B. has research support from Daiichi Sankyo and Roche, honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo; as well as travel support from Roche, Amgen, Daiichi Sankyo, and AbbVie.GW.P. has the following to declare: Advisory Role\/Speaker's Fee: Merck Serono, Roche, Amgen, Sanofi, Lilly, Servier, Taiho, Bayer, Halozyme, BMS, MSD, Celgene, Pierre Fabre, Shire, CECOG, Astra Zeneca. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. The study was approved by the ethics committee of the Medical University of Vienna (reference number: 1600\/2021). The risk of publication of sensitive patient data was minimized by restrictions of data accession and pseudonymized statistical analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective design no separate informed consent was necessary in the scope of this study. This is in line with local ethical standards and was approved by the ethics committee of the Medical University of Vienna (reference number: 1600\/2021).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}